期刊文献+

吉西他滨治疗恶性血液病的研究进展 被引量:5

下载PDF
导出
摘要 古西他滨(化学名2'-脱氧2',2'二氟胞苷盐酸盐,dFdC)作为一种新型的脱氧胞苷类似物, 在实体瘤如非小细胞肺癌、胰腺癌治疗中获得明确的疗效,但在恶性血液疾病的应用尚处于临床试验阶段。本文在介绍dFdC的药效学和药代动力学的基础上,对国外开展dFdC治疗白血病、淋巴瘤及多发性骨髓瘤的临床试验结果进行介绍和评估。
作者 易克 许小平
出处 《国外医学(输血及血液学分册)》 2005年第4期364-367,共4页 Foreign Medical Sciences(Section of Blood Transfusion and Heanatology)
  • 相关文献

参考文献21

  • 1Azria D, Coelho M, Larbouret C, et al. Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice. Cancer Radiother,2004,8(Suppl 1):S106-113. 被引量:1
  • 2Ruiz van Haperen VW, Veerman G, Vermorken JB, et al. 2',2'-Difluoro-deoxycytidine (gemcitabine)incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol,1993, 46(4):762-766. 被引量:1
  • 3Plunkett W, Huang P, Xu Y, et al. Gemcitabine: Metabolism,mechanisms of action, and self-potentiation. Semin Oncol, 1995,22 (Suppl 11):3-10. 被引量:1
  • 4Grunewald R, Kantarjian H, Du M, et al. Gemcitabine (2',2'-difluoro deoxy cytidine) in leukemia: A phase I clinical, plasma and cellular pharmacology study. J Clin Oncol, 1992,10(3): 406-413. 被引量:1
  • 5Waselenko JK, Grever MR, Shinn CA, et al. Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia. Leuk Res, 2001, 25 (6): 435-440. 被引量:1
  • 6Verschuur AC, Van Gennip AH, Leen R, et al. Increased cytotoxicity of 2', 2'-difluoro-2'-deoxycy-- tidine in human leukemic cell-lines after a preincubation with cyclopentenyl cytosine. N ucleo- sides Nucleotides Nucleic Acids, 2004,23 (8-9):1517-1521. 被引量:1
  • 7Rizzieri DA, Bass AJ, Rosner GL, et al. Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia. J Clin Oncol, 2002, 20(3) :674-679. 被引量:1
  • 8Apostolidou E, Estey E, Cortes J, et al. Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia. Leuk Res, 2003,27 (4): 301-304. 被引量:1
  • 9Bass A J, Gockerman JP, Hammett E, et al. Phase I evaluation of prolonged- infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol, 2002, 20 (13):2995-3000. 被引量:1
  • 10Rizzieri DA, Ibom VK, Moore JO, et al. Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. Clin Cancer Res, 2003, 9(2):663-668. 被引量:1

同被引文献29

  • 1孙玲,王峰,孙慧,乐晓萍,刘林湘,刘延方,王芳,王一浩,马鸿雁,张钦宪.c-myc反义寡核苷酸对HL-60细胞端粒酶活性影响及诱导凋亡作用[J].中国实验血液学杂志,2005,13(4):605-609. 被引量:9
  • 2沈志祥,周励.复发难治性淋巴瘤的治疗进展[J].临床内科杂志,2005,22(9):580-582. 被引量:18
  • 3何永明.吉西他滨联合方案治疗复发或难治性非霍奇金淋巴瘤5例[J].白血病.淋巴瘤,2006,15(1):49-50. 被引量:8
  • 4甘雨,徐惠波,孙晓波.三七总皂苷的药理作用研究进展[J].时珍国医国药,2007,18(5):1251-1252. 被引量:119
  • 5Peters GJ, van der Wilt CL, van Moorsel CJ, et al. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther, 2000; 87(2 -3) : 227 -253. 被引量:1
  • 6Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase I//trial. Lung Cancer, 2006; 52(2) : 155 - 163. 被引量:1
  • 7Iwasaki H, Huang P, Keating MJ, et al. Differential incorporation of Ara-C, Gemcitabine, and Fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood, 1997 ; 90( 1 ) : 270 - 278. 被引量:1
  • 8Giovannetti E, Mey V, Loni L, et al. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid ceils. Pharmacol Res, 2007 ;55 (4) : 343 - 349. 被引量:1
  • 9Ruiz van Haperen VW, Veerman G, Vermorken JB, et al. 2',2'- Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol, 1993 ;46(4) : 762 - 766. 被引量:1
  • 10Shanks RH, Rizzieri DA, Flowers JL, et al. Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. Clinical Cancer Res, 2005 ; 11 ( 11 ) : 4225 - 4233. 被引量:1

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部